Article
Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
Journal of acquired immune deficiency syndromes (1999) - 15 Apr 2015
Andreatta Kristen, Kulkarni Rima, Abram Michael E, Nguyen Thai, Cao Huyen, Miller Michael D, White Kirsten L
Abstract excerpt
BACKGROUND: Stably suppressed HIV-1-infected patients that switched to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) from regimens containing FTC/TDF plus a ritonavir-boosted protease inhibitor (PI + RTV), nonnucleoside reverse transcriptase inhibitor (NNRTI), or raltegravir in phase 3 studies STRATEGY-PI, STRATEGY-NNRTI, and GS-US-236-0123 maintained high rates of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.